PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDarunavir
Prezista(darunavir)
Darunavir, Prezista, Rezolsta, Symtuza (darunavir) is a small molecule pharmaceutical. Darunavir was first approved as Prezista on 2006-06-23. It is used to treat acquired immunodeficiency syndrome in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
Darunavir, Prezista (discontinued: Darunavir, Prezista)
Combinations
Symtuza
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Darunavir
Tradename
Company
Number
Date
Products
PREZISTAJohnson & JohnsonN-021976 RX2008-02-25
4 products, RLD
PREZISTAJohnson & JohnsonN-202895 RX2011-12-16
1 products, RLD, RS
Show 1 discontinued
Cobicistat
+
Darunavir
+
Emtricitabine
+
Tenofovir alafenamide fumarate
Tradename
Company
Number
Date
Products
SYMTUZAJohnson & JohnsonN-210455 RX2018-07-17
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
darunavirANDA2025-03-19
darunavir 600 and 800 mgANDA2025-06-05
prezcobixNew Drug Application2025-04-08
prezistaNew Drug Application2025-08-29
symtuzaNew Drug Application2024-07-23
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
acquired immunodeficiency syndromeEFO_0000765D000163B20
hiv infectionsEFO_0000764D015658B20
chronic hepatitis bEFO_0004239D019694B18.1
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Cobicistat / Darunavir / Emtricitabine / Tenofovir Alafenamide Fumarate, Symtuza, Janssen Prods
107865182038-07-19U-2978
87540652032-08-15DS, DPU-2352, U-2765
92967692032-08-15DS, DPU-2352, U-2765
73907912025-04-17DS, DP
Cobicistat / Darunavir, Prezcobix, Janssen Prods
100397182032-10-06DP
81483742029-09-03DS, DPU-1279, U-2353, U-2364, U-2365, U-2766, U-2767, U-2768, U-2939
77006452026-12-26DS, DP
85189872024-02-16DS, DP
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AE: Protease inhibitors, direct acting antivirals
— J05AE10: Darunavir
— J05AR: Antivirals for treatment of hiv infections, combinations
— J05AR14: Darunavir and cobicistat
— J05AR22: Emtricitabine, tenofovir alafenamide, darunavir and cobicistat
— J05AR26: Darunavir and ritonavir
HCPCS
No data
Clinical
Clinical Trials
285 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B202239543928171
Acquired immunodeficiency syndromeD000163EFO_0000765B20121626101372
HivD006678—O98.71171418655
Hiv-1D015497——4894125
InfectionsD007239EFO_0000544—6753222
Healthy volunteers/patients———18——3—21
Hepatitis cD006526—B19.2441119
Covid-19D000086382—U07.1—33128
Communicable diseasesD003141——1322—7
Immunologic deficiency syndromesD007153—D84.9122116
Show 38 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv-2D015498——111—36
Virus diseasesD014777—B34111——3
PneumoniaD011014EFO_0003106J18——1—23
ViremiaD014766—B34.9—11——2
Liver cirrhosisD008103EFO_0001422K74.0—21——2
CoronavirusD017934————1—12
Occupational injuriesD060051————1——1
Treatment-resistant depressive disorderD061218————1——1
PregnancyD011247EFO_0002950Z33.1——1——1
Pneumocystis pneumoniaD011020EFO_0007448B59——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Coronavirus infectionsD018352EFO_0007224B34.2—2———2
Sars-cov-2D000086402———2———2
ContraceptionD003267———2———2
Renal insufficiencyD051437—N19—1———1
FibrosisD005355———1———1
Viral pneumoniaD011024EFO_0007541J12.9—1———1
DyslipidemiasD050171——11———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HemorrhageD006470MP_0001914R581————1
ThrombosisD013927——1————1
Opioid-related disordersD009293EFO_0005611F111————1
Insulin resistanceD007333EFO_0002614E88.8191————1
Amyotrophic lateral sclerosisD000690EFO_0000253G12.211————1
HepacivirusD016174——1————1
AsthmaD001249EFO_0000270J451————1
PharmacokineticsD010599——1————1
Latent tuberculosisD055985—Z22.71————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
TuberculosisD014376EFO_0000774A15-A19————11
Chronic hepatitis bD019694EFO_0004239B18.1————11
Respiratory insufficiencyD012131—J96.9————11
DiarrheaD003967—R19.7————11
MorbidityD009017——————11
Therapeutic equivalencyD013810——————11
MalnutritionD044342EFO_0008572E40-E46————11
DementiaD003704EFO_0003862F03————11
AgingD000375GO_0007568R41.81————11
Bone fracturesD050723EFO_0003931T14.8————11
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDarunavir
INNdarunavir
Description
Darunavir is an N,N-disubstituted benzenesulfonamide bearing an unsubstituted amino group at the 4-position, used for the treatment of HIV infection. A second-generation HIV protease inhibitor, darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including those from treatment-experienced patients with multiple resistance mutations to other protease inhibitors. It has a role as a HIV protease inhibitor and an antiviral drug. It is a furofuran, a carbamate ester and a sulfonamide.
Classification
Small molecule
Drug classantivirals: HIV protease inhibitors (saquinavir type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1
Identifiers
PDB—
CAS-ID206361-99-1
RxCUI—
ChEMBL IDCHEMBL1323
ChEBI ID367163
PubChem CID213039
DrugBankDB01264
UNII IDYO603Y8113 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Darunavir
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 12,346 documents
View more details
Safety
Black-box Warning
Black-box warning for: Darunavir, Symtuza
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
16,308 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use